{"id":11216,"date":"2019-03-27T14:45:58","date_gmt":"2019-03-27T13:45:58","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=11216"},"modified":"2021-03-11T14:29:17","modified_gmt":"2021-03-11T13:29:17","slug":"camurus-has-carried-out-a-rights-issue-of-approximately-sek-403-million","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/en\/assignment\/camurus-has-carried-out-a-rights-issue-of-approximately-sek-403-million\/","title":{"rendered":"Camurus has carried out a rights issue of approximately SEK 403 million"},"content":{"rendered":"<p class=\"preamble\">Camurus has carried out a new issue of shares with preferential rights for the company&#8217;s shareholders raising approximately SEK 403 million.<\/p>\n<p>Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company&#8217;s proprietary FluidCrystal\u00ae drug delivery technologies and its extensive R&amp;D expertise. Camurus&#8217; clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus&#8217; shares are listed on Nasdaq Stockholm.<\/p>\n<p>Camurus was advised by Mannheimer Swartling in the transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Camurus has carried out a new issue of shares with preferential rights for the company&#8217;s shareholders raising approximately SEK 403 million. Camurus is a Swedish\u2026<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4313],"tags":[],"class_list":["post-11216","post","type-post","status-publish","format-standard","hentry","category-assignment","business-group-public-ma-and-equity-capital-markets"],"acf":[],"lang":"en","translations":{"en":11216,"sv":11214},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11216"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=11216"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11216\/revisions"}],"predecessor-version":[{"id":14497,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/11216\/revisions\/14497"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=11216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=11216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=11216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}